Argentina Glp-1 Receptor Agonist Market Size & Outlook
Argentina glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Argentina glp-1 receptor agonist market highlights
- The Argentina glp-1 receptor agonist market generated a revenue of USD 220.4 million in 2023 and is expected to reach USD 873.8 million by 2030.
- The Argentina market is expected to grow at a CAGR of 21.7% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 220.4 million |
| Market revenue in 2030 | USD 873.8 million |
| Growth rate | 21.7% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Argentina accounted for 0.6% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- Argentina is the fastest growing regional market in Latin America and is projected to reach USD 873.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Argentina glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 34.94% in 2023. Horizon Databook has segmented the Argentina glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
Government support to improve the healthcare system and facilitate access to advanced diagnosis & treatment is expected to fuel the market in Argentina. The pharmaceutical sector in the country is robust, featuring 402 licensed manufacturers—362 specializing in pharmaceutical products and 40 in starting materials.
Researchers in the country possess the capability for comprehensive pharmaceutical activities, including R&D to discover new active substances, produce Active Pharmaceutical Ingredients (APIs), formulate pharmaceutical products from them, and repackage finished dosage forms.
This infrastructure supports a well-rounded pharmaceutical industry with significant potential for both innovation and production. The market growth is attributed to the rising prevalence of diabetes in the country and the steps taken to promote initiatives that contribute to reducing the rise of overweight & obesity among the population.
Reasons to subscribe to Argentina glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Argentina glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Argentina glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Argentina glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Argentina GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
